论文部分内容阅读
为探讨细胞增殖活性与喉癌生物学行为及其预后的关系，作者以增殖细胞核抗原（ＰＣＮＡ）作为细胞增殖的标记物，用免疫组化技术对１１例喉上皮单纯性增生（ＳＨＥ）、３２例非典型性增生（ＡＨＥ）及４２例喉鳞癌（ＬＳＣＣ）的细胞增殖活性进行原位检测。结果显示：上述三组病例的ＰＣＮＡ指数分别为９５７％，２７３３％和６８０５％；在高中低分化ＬＳＣＣ中，ＰＣＮＡ指数分别为６３６８％，６９５７％和７１７８％，其差异有高度显著性（Ｐ＜００１），而在Ⅰ～Ⅳ期喉癌中，ＰＣＮＡ指数分别为６３８３％，７０８２％、６６２６％和６９０４％，其差异无统计学意义（Ｐ＞００５）；ＰＣＮＡ指数与喉癌患者生存时间呈显著负相关（ｒ＝－０６２４３），但与局部复发、颈淋巴结转移无关。由此提示：以ＰＣＮＡ作标志物研究喉癌细胞增殖活性，有助于认识喉癌的本质、发展趋势及预后
To explore the relationship between cell proliferation activity and biological behavior and prognosis of laryngeal carcinoma, the authors used proliferating cell nuclear antigen (PC-NA) as a marker of cell proliferation and 11 cases of laryngeal epithelial simple hyperplasia (SHE) by immunohistochemical technique. , 32 cases of atypical hyperplasia (AHE) and 42 cases of laryngeal squamous cell carcinoma (LSCC) cell proliferation activity in situ detection. The results showed that the PCNA indices of the above three groups were 9.5%, 27%, 33%, and 68.5%, respectively. In the high-grade, low-differentiation, LSCC, the PCNA indexes were 63.8%, 69.7%, and 71%, respectively. 78%, the difference was highly significant (P<001), while in the I-IV laryngeal cancer, the PCNA index was 6383%, 7082%, 6626%, and 6904% respectively. The difference was not statistically significant (P>005); PCNA index was significantly negatively correlated with the survival time of patients with laryngeal cancer (r=-06243), but had no relationship with local recurrence or cervical lymph node metastasis. This suggests that the use of PCNA as a marker to study the proliferative activity of laryngeal cancer cells helps to understand the nature, development trend and prognosis of laryngeal cancer.